Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG

Modern Pathology

Volumn 27, Issue 4, 2014, Pages 609-620

  Warrick, Joshua I ^a   Tomlins, Scott A ^a   Carskadon, Shannon L ^a   Young, Allison M ^a   Siddiqui, Javed ^a   Wei, John T ^a   Chinnaiyan, Arul M ^a   Kunju, Lakshmi P ^a   Palanisamy, Nallasivam ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

PCA3; prostate cancer; RNA in situ hybridization

Indexed keywords

PCA3; UNCLASSIFIED DRUG; UNTRANSLATED RNA; ONCOPROTEIN; PROSTATE CANCER ANTIGEN 3, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CORRELATION ANALYSIS; ERG GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TISSUE LEVEL; TMPRSS2 GENE; URINALYSIS; COMPARATIVE STUDY; EARLY DIAGNOSIS; GENE REARRANGEMENT; GENETICS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS; URINE;

ANTIGENS, NEOPLASM; EARLY DETECTION OF CANCER; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; ONCOGENE PROTEINS, FUSION; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RNA, UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL;

EID: 84897526502     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.169     Document Type: Article

References (28)

1. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59: 5975-5979.
2. Schmidt U, Fuessel S, Koch R, et al. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006;66:1521-1534.
3. Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007;20:1121-1127.
4. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
5. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599.
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
7. Mosquera J-M, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14: 3380-3385.
8. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011;29:3659-3668.
9. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-286.
10. Park K, Tomlins SA, Mudaliar KM, et al. Antibodybased detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010;12:590-598.
11. Tomlins SA, Palanisamy N, Siddiqui J, et al. Antibodybased detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Arch Pathol Lab Med 2012;136:935-946.
12. Young A, Palanisamy N, Siddiqui J, et al. Correlation of Urine TMPRSS2:ERG and PCA3 to ERG\+ and Total Prostate Cancer Burden. Am J Clin Pathol 2012;138: 685-696.
13. Tomlins SA, Aubin SMJ, Siddiqui J, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3:94-72.
14. Cornu J-N, Cancel-Tassin G, Egrot C, et al. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2012;73:242-249.
15. Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013;19:2442-2450.
16. Stephan C, Jung K, Semjonow A, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum prostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59: 280-288.
17. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60: 264-269.
18. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-535.
19. Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012;15:165-169.
20. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011;459: 441-447.
21. He H, Magi-Galluzzi C, Li J, et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with 'atypical glands suspicious for cancer'. Am J Surg Pathol 2011;35: 608-614.
22. Jenkins RB, Qian J, Lee HK, et al. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res 1998;58:759-766.
23. Qian J, Bostwick DG, Takahashi S, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995;55:5408-5414.
24. Vukovic B, Park PC, Al-Maghrabi J, et al. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003;22:1978-1987.
25. Kunju LP, Chinnaiyan AM, Shah RB. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer. Histopathology 2005;47: 587-596.
26. Auprich M, Bjartell A, FK-H Chun, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011;60:1045-1054.
27. Groskopf J, Aubin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52: 1089-1095.
28. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts t umour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59: 422-429.